Follow the 지놈앤컴퍼니 share price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 지놈앤컴퍼니 has logged 49 reports. Market capitalisation: €122.7bn. The latest transaction was reported on 30 April 2026 (Purchase). Among the most active insiders: 배지수. The full history is accessible without an account.
49
Insider Decl.
n/a
Thresholds
€45,606
8 ops.
Buy Volume
€88,901
4 ops.
Sell Volume
22Σ signal
Buys €45,606€88,901 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,663 of 29,062 companies
20.0
score / 100
Value
12
Quality
28
FCF yld-13%
Earn yld-4.5%
EV/EBITDA59.6x
ROE-7.1%
Gross mgn55%
Net mgn-26%
Debt/EBITDA7.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Genome & Company es una empresa farmacéutica y de atención médica que cotiza en el XKRX. Se especializa en tecnologías genómicas y soluciones de salud personalizadas.